## FORM 4

Check this box if no longer subjection 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

ct to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL							
OMB Number: 3235-02								
l	Estimated average burden							
l	hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Brockstedt Dirk G.  (Last) (First) (Middle)  C/O ADURO BIOTECH, INC.  740 HEINZ AVENUE						2. Issuer Name and Ticker or Trading Symbol ADURO BIOTECH, INC. [ ADRO ]									ationship of Reporting  all applicable)  Director  Officer (give title		g Person(s) to Iss 10% Ov Other (s		vner	
						3. Date of Earliest Transaction (Month/Day/Year) 11/06/2017									below) below)  EVP of Research and Dev.					
(Street) BERKEI (City)		tate)	94710 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)								ne) X	dual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day)			tion	on 2A. Deemed Execution Date,			3. Transa Code ( 8)	ction	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			5. Amo and 5) Securit Benefic		int of es ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
				11/06/5	24.5				Code	v	Amount	(A) or (D)	Price	(	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
				11/06/2		-		M S <sup>(1)</sup>		4,123 4,123	A D	\$0.5 \$8.035			7,841       3,718		D D			
		Т	able II								posed of converti				ned	·		·		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	on Date,	4. Transa Code ( 8)				6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Deri Seci	. Price of perivative security nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	is Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares	1						
Stock Option (Right to	\$0.52	11/06/2017			M			4,123	(3)		10/24/2021	Common Stock	4,123	\$	0.00	51,833		D		

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2017.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.00 to \$8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The shares subject to the Option became fully vested and exercisable as of April 15, 2015.

## Remarks:

/s/ Jennifer Lew, Attorney-in-**Fact** 

11/08/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.